Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell trafficking

Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation

(2016) H. Schwartz et al.   CANCER RESEARCH

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease

(2016) Kuti Baruch et al.   NATURE MEDICINE

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

(2016) Justine V. Cohen et al.   Pigment Cell & Melanoma Research

Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases

(2016) Nora Rippaus et al.   Oncotarget

Evolving treatment options for melanoma brain metastases

(2015) Thankamma Ajithkumar et al.   LANCET ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

AKT1 Activation Promotes Development of Melanoma Metastases

(2015) Joseph H. Cho et al.   Cell Reports

Immunotherapy for cancer in the central nervous system: Current and future directions

(2015) David C. Binder et al.   OncoImmunology

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site

(2014) Vanesa Alonso-Camino et al.   MOLECULAR THERAPY

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair

(2013) Gilad Kunis et al.   BRAIN

Manipulating the PD-1 pathway to improve immunity

(2013) Alice O Kamphorst et al.   CURRENT OPINION IN IMMUNOLOGY

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The microglial sensome revealed by direct RNA sequencing

(2013) Suzanne E Hickman et al.   NATURE NEUROSCIENCE

Melanoma metastasis: new concepts and evolving paradigms

(2013) W E Damsky et al.   ONCOGENE

Abstract 5209: Prostate cancer progenitor cells have distinct DNA methylation profile which changes upon differentiation

(2012) Davide Pellacani et al.   CANCER RESEARCH

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Unknown

(2012) Salvatore Coniglio et al.   MOLECULAR MEDICINE

Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets

(2012) Catriona Prendergast et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors

(2012) Faruk Tas   Journal of Oncology

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

Prognostic factors for survival in melanoma patients with brain metastases

(2010) Michael A. Davies et al.   CANCER

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

(2010) Cole Trapnell et al.   NATURE BIOTECHNOLOGY

Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma

(2009) F. Zhao et al.   CLINICAL CANCER RESEARCH